GeneDx Holdings Corp. (NASDAQ:WGS) is without doubt one of the greatest digital well being shares to purchase now.
On October 29, 2025, Guggenheim lifted GeneDx (NASDAQ:WGS) to a $170 value goal (Purchase) after the corporate’s blow-out Q3 announcement a day earlier. GeneDx had simply reported income of $116.7 million, up 52% 12 months over 12 months and roughly ~12% above Avenue; exome and genome income reached $98.9 million, up 65%, with exome/genome take a look at volumes up 33%. Gross profitability widened too: adjusted gross margin improved to 74% (GAAP 72%), and adjusted web revenue rose to $14.7 million.
Tonhom1009/Shutterstock.com
That print underpins Guggenheim’s call-outs, with exome and genome volumes nonetheless compounding, ASPs operating increased, and gross margin trending up, therefore the larger goal. Administration additionally raised full-year 2025 steering to $425–$428 million in income and 53–55% progress in exome/genome income, alongside a 70–71% adjusted gross-margin information.
Crucially, Guggenheim addressed the 2026 spend feedback: even with stepping up opex subsequent 12 months, the agency doesn’t learn that as a return to damaging EPS, framing it as an alternative as funding towards a now-proven scale curve in pediatric and rare-disease genomics.
GeneDx Holdings Corp. (NASDAQ:WGS) focuses on genomic testing, with a give attention to whole-exome and whole-genome sequencing for pediatric and uncommon issues. Its choices additionally embrace information options that help medical decision-making and precision medication.
Whereas we acknowledge the potential of WGS as an funding, we imagine sure AI shares supply better upside potential and carry much less draw back danger. For those who’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None.